Aktuelle Publikationen der GBG
Originalarbeiten 2010
Untch M, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer J. U, Thomssen C, Costa S.D, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G for the German Breast Group and AGO Breast Group: Neoadjuvant Treatment with Trastuzumab in HER2-positive Breast Cancer: Results from GeparQuatro Study. Accepted J Clin Oncol
von Minckwitz G, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch K, Kühn T, du Bois A, Blohmer J.U, Thomssen C, Costa S.D, Jackisch C, Kaufmann M, Mehta K, Untch M: Capecitabine in Addition to Anthracycline / Taxane-based Neoadjuvant Treatment in Patients with Primary Breast Cancer: The Phase III GeparQuattro Study. Accepted J Clin Oncol
Denkert C, Loibl S, Noske A, Roller M, Müller B, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Törne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G: Tumor-associated Lymphocytes as an Independent Predictor of Response to Neo-adjuvant Chemotherapy in Breast Cancer. J Clin Oncol 28(1):105-13, 2010
Eiermann W, Graf E, Ataseven B, Conrad B, Hilfrich J, Massinger-Biebl H, Vescia S, Loibl S, von Minckwitz G, Schumacher M, Kaufmann M; for the German Adjuvant Breast Cancer Group: Dose-intensifed epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph npdes: Results of a randomised trial (GABG-IV E-93) - The German Adjuvant Breast Cancer Group. Eur J Cancer 46(1):84-94, 2010
Kongressbeiträge 2010 (Abstracts, Poster, Präsentationen)
EBCC 2010
Loibl S, Bontenbal M, Ring A, UFK FFM NN, Crivellari D, Fehm T, Heinrigs M, Lenhard M, Mehta K, von Minckwitz G: Breast cancer during pregnancy – a prospective and retrospective European registry (GBG-20/BIG02-03), Accepted as poster discussion which is scheduled as a part of the poster session on "Epidemiology, management care and pregnancy" on 26 March 2010.
Loibl S, Conrad B, Warm M, Schwedler K, Gerber B5 Schrader I, Eidtmann H, Linder M, Mehta K, von Minckwitz G: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib (S) followed by paclitaxel (Pw) + sorafenib (S) in women with previously untreated primary breast cancer (BC) (GBG 45), Accepted as poster which is scheduled as a part of the poster session on "Targeting and profiling predictive and prognostic factors" on 24 March 2010.
von Minckwitz G, Zahm MD, Eidtmann H, Tesch H, du Bois A, Schwedler K, Hilfrich J, Jackisch C, Mehta K, Gerber B: Zoledronic acid (ZOL) as add on therapy in patients with tumor residuals after neoadjuvant chemotherapy for primary breast cancer – first interim safety analysis of the NATAN study (GBG 36), Accepted as poster which is scheduled as a part of poster session on "Adjuvant and neo-adjuvant therapy" on 24 March 2010.
von Minckwitz G, Müller B, Loibl S, Blohmer J.U, du Bois A, Huober J, Fend F, Budczies J, Accepted as Denkert C, on behalf of the German Breast Group: PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy, Accepted as oral presentation in the Clinical Science Symposium "Gene profiling and treatment of disease" which will be held on 26 March 2010.
DKK 2010
Loibl S, Conrad B, Warm M, Schwedler K, Gerber H, Schrader I, Eidtmann H, Magnani D, Mehta K, von Minckwitz G: SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib (S) followed by paclitaxel (Pw) + sorafenib (S) in women with previously untreated primary breast cancer (BC) (GBG 45), Accepted as Poster discussion
ZORO: prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37), Accepted as Poster discussion
Originalarbeiten 2009
Costa S.D, Loibl S, Kaufmann M, Zahm D.M, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer J.U, Eiermann W, Weiss E, Tesch H, Gerber B, Baumann K.H, Thomssen C, Breitbach G.P, Ibishi S, Jackisch C, Mehta K, von Minckwitz g, for the German Breast Group: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: A secondary analysis of the GEPARTRIO trial data. J Clin Oncol 28(1):83-91, 2009
Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F, Stauber R, Kaufmann M, Nekljudova V, Loibl S: VEGF-A and i-NOS Expression are Prognostic Factors in Serous Epithelial Ovarian Carcinomas after Complete Surgical Resection. J. Clin. Pathol 62(5):448-54, 2009
Darb-Esfahani S, Loibl S, Müller B.M, Roller M, Denkert C, Komor M, Schlüns K, Blohmer J.U, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G: Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res. 11(5):R69, 2009
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemother Pharmacol 63(5):953-8, 2009
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh F.E, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann K. H, Clemens M.R, Duerr R, Uleer C, Andersson M, Stein R.C, Nekljudova V, Loibl S: Trastuzumab beyond progression in humen epidermal growth factor receptor 2-positive advance breast cancer: a german breast group 26/Breast international group 03-05 study. J Clin Oncol 27(12):1999-2006, 2009
Kongressbeiträge 2009 (Abstracts, Poster, Präsentationen)
St. Gallen
ICE study: Ibandronate with or without Capecitabine in Elderly Patients with Early Breast Cancer (Abstract)
ASCO
ESMO/ECCO
ZORO study: Präsentation: siehe ASCO
SABCS
Originalarbeiten 2008
Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Eggemann H, Nekljudova V, Sommer H, Kiechle M, Kummel S: Clinical feasibility of (neo)adjuvant taxane based chemotherapy in elderly patients: an analysis of > 4,500 patients from four german randomized breast cancer trials. Breast Cancer Res 10(5):R77, 2008
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa C.D, Jackisch C, Loibl S, Mehta K, Kaufmann M: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100(8):542-51, 2008
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa S.D, Jackisch C, Loibl S, Mehta K, Kaufmann M: Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100(8):552-62, 2008
von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa S.D, Jackisch C, Grasshoff S.T, Vescia S, Skacel T, Loibl S, Mehta K, Kaufmann M: Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292-8, 2008
von Minckwitz G, Sinn H.P, Raab G, Loibl S, Blohmer J.U, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa S.D, Caputo A, Kaufmann M: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10(2):R30, 2008
Engels K, Knauer S.K, Loibl S, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber R.H: NO signalling confers cytoprotectivity the surviving network in ovarian carcinomas. Cancer Res 68(13):5159-66, 2008
Abstracts 2008
von Minckwitz G, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J.U, Costa S.D, Loibl S, Volz D, Untch M: Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing hemotherapy. Cancer Res 2009, 69(Suppl.):(2). (SABCS 2008, Oral Presentation # 79)
Loibl S, Müller B, Roller M, Kronenwett R, Darb-Esfahani S, Komor M, von Toerne C, Wirtz R, von Minckwitz G, Denkert C on behalf of the German Breast Group: Local versus Central HER2 Immunohistochemistry Correlates with kinetic RT-PCR but Only Central Immunohistochemistry and RT-PCR predict Pathological Complete Response: Results from the Neoadjuvant Multicenter GeparTrio Trial. Cancer Res 2009, 69(Suppl.):(2). (SABCS 2008, Poster # 1070)
von Minckwitz G, Rezai M, Loibl S, Fasching P.A, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M for the German Breast Group and AGO Breast Group: Effect of trastuzumab on pathologic complete response rate of neoadjuvant EC-docetaxel treatment in HER2-overexpressing breast cancer: Results of the phase III GeparQuattro study. Breast Cancer Symposium, Proceeding Book 2008, Astract # 226, Page Nr. 198 (ASCO Breast 2008)
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – the RiTa trial. Breast Cancer Symposium, Proceeding Book 2008, Astract Nr. 178, Page Nr. 174 (ASCO Breast 2008)
von Minckwitz G, Zielinski C, Maartense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, De Jongh F.E, Kaufmann M, Loibl S: Capecitabine vs. Capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment – the TBP phase III study (GBG 26 / BIG 3-05). Ann Oncol 19(8):63, 2008 (ESMO 2008, Abstract # 133O)
Loibl S, Murmann C, Schwedler K, Warm M, Müller L, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – the RiTa trial. Ann Oncol 19(8):69, 2008 (ESMO 2008, Abstract # 155P)
Untch M, Fasching P.A, Bauerfeind I, Conrad U, Camara O, Fett W, Kuzeder W, Lück H, Loibl S, von Minckwitz G: PREPARE trial. A randomized phase III trial comparing preoperative, dose dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin / cyclophosphamide followed by paclitaxel darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 26(15S):10s, 2008 (ASCO 2008 Abstarct # 517)
von Minckwitz G, Zielinski C, Maartense E, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Kaufmann M, Loibl S: Capecitabine vs. capecitabine + trastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26 / BIG 3-05). J Clin Oncol 26(15S):47s, 2008 (ASCO 2008, Abstract # 1025)
Untch M, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G: Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophoshamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study "GeparQuatro". Eur J Cancer 6(7):47, 2008 (EBCC Berlin 2008)
Loibl S, Ring A, von Minckwitz A, Heinrigs M, Lenhard M, Amant F, Weiss C, Augustin D, Nekljudova V, Kaufmann M: Breast cancer during pregnancy – a prospective and retrospective registry (GBG-20/BIG02-03). Eur J Cancer 6(7):68, 2008 (EBCC Berlin 2008)
Vescia S, von Minckwitz G, Loibl S, Jackisch C, Paepke S, Nestle-Kremmling C, Lux M.P, Maass N, Schmutzler R, Kaufmann M: The Giss Trial: A pilot phase randomized prevention trial of screening plus goserelin plus ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer. Eur J Cancer 6(7):72, 2008 (EBCC 2008)
Loibl S: Young woman and fertility in breast cancer. Eur J Cancer 6(7):105, 2008 (EBCC Berlin 2008)
von Minckwitz G, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M: Capecitabine given concomitantly or in sequence with EC ---> docetaxel as neoadjuvant treatment for early breast cancer: GeparQuatro - a GBG/AGO intergroup study. Eur J Cancer 6(7):108, 2008 (EBCC Berlin 2008)
Loibl S, Murmann C, Schwedler K, Warm M, Heinrich G, Nekljudova V, von Minckwitz G: A multicentre phase I dose finding study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with anthracycline pretreated metastatic breast cancer – The RiTa trial. Internal Journal for Cancer Research and Treatment 31(1), 2008 (DKK Berlin 2008)
Originalarbeiten 2007
Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta K, Kaufmann M: Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 18(4):689-93, 2007
Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, Conrad B, Gademann G, Albert U.S, Loibl S, von Minckwitz G, Schumacher M: A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. Eur J Cancer 43(16):2351-8, 2007
Rody A, Karn T, Solbach C, Gaetje R, Munnes M, Kissler S, Ruckhaberle E, von Minckwitz G, Loibl S, Holtrich U, Kaufmann: The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16(3):235-40, 2007
Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, allo-Danebrock R, Ruckhaberle E, Metzler D, Ahr A, Solbach C, Karn T, Kaufmann M: Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 13(4):1115-22, 2007
Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 16(1):86-93, 2007
Abstracts 2007
von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Houber J, Costa S, Loibl S: Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from the GEPARTRIO study. J Clin Oncol 25(18S):13s, 2007 (ASCO 2007, # 542)
Loibl S, Schmidt M, Marquart, Houber J, Bischoff J, von Minckwitz G, Mehta K, Kaufmann M: Mitomycin C in combination with capecitabine (Mi-Cap) as chemotherapy in breast cancer with extensive liver metastases and impaired hepatic function: A non-randomized multicentre phase II. J Clin Oncol 25(18S):714s, 2007 (ASCO 2007, Nr. 19597)
Mueller V, Reithdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K: Prospective monitoring of circulating tumor cells in bresat cancer patients treated with primary systemic therapy-A translational project of the German Breast Group study GeparQuattro. J Clin Oncol 25(18S):735s, 2007 (ASCO 2007, Nr.21085)
Loibl S, Pfisterer J, Wimberger P, Kurzeder C, du Bois A, Sehouli J, Belau A, Burchardi N, Vergote I, Wagner U: Randomised, multicenter, 2-dose-level, open label, phase IIa study with the intraperitoneally infused trifunctional biospecific antibody catumaxomab (anti-EpCAM x anti CD3) to select the better dose level inplatinum refractory epithelial ovarian cancer patients. Eur J Cancer 5(4):312, 2008 (ECCO 2007, # 5005, Oral Presentation)
Reithdorf S, Loibl S, Komor M, Houber J, Schrader I, Conrad U, Untch M, von Minckwitz G, Pantel K, Mueller V: Incidence and kinetics of circulating tumor cells in breast cancer patients treated with primary systemic therapy including trastuzumab for patients with HER2-positive tumors a translational project within the study Gepar Quattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.5025), Page Nr. S214
Rody A, Holtrich U, Gaetje R, Engels K, von Minckwitz G, Loibl S, Gehrmann M, Ruckhaberle E, Ahr A, Solbach C, Karn T, Kaufmann M: Breast cancer classication according to stem cell-like features and its relevance for systemic adjuvant treatment decision. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.3103), Page Nr. S161
Untch M, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, von Minckwitz G: Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/ cyclophosphamide docetaxelcapecitabine as neoadjuvant treatment of HER2 verexpressing primary breast cancer. First analysis of the GBG/AGO intergroup-study GeparQuattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.5053), Page nr. S224
von Minckwitz G, Rezai M, Loibl S, Fasching P, Houber J, Tesch H, Bauerfeind I, Hilfrich J, Mehta K, Untch M: Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study GeparQuattro. Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.79), Page Nr. S21
von Minckwitz G, Vogel P, Schmidt M, Eidtmann H, Cufer T, de Jongh F, Maartense E, Zielinski C, Andersson M, Stein R, Nekljudova V, Loibl S: Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer the TBP study (GBG 26/BIG 3-05). Breast Cancer Res Tr 106(1), 2007 (SABCS 2007, Nr.4056), Page Nr. S185
Loibl S, von Minckwitz G, Heinrigs M, Lenhard M, Amant F, Wolf I, Weiss C, Augustin D, Nekljudova V, Kaufmann M: Breast cancer during pregnancy – a prospective and retrospective registry (GBG-20/BIG02-03). ESGO 2007
von Minckwitz G, Blohmer J.U, Raab G, Steffen J, Kaufmann M, Loehr A, Gerber B, Heinrich G, Eidtmann H, Hilfrich J, Jackisch C, Costa S.D, Houber J, Bühler H, Loibl S: Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline / taxane based regimen in the multicenter GeparTrio trial. AACR 2007
Kontakt:
Lejla Valjevcic
Fon: +49 6102 7480-418
Fax: +49 6102 7480-118
Diese E-Mail-Adresse ist gegen Spambots geschützt! Sie müssen JavaScript aktivieren, damit Sie sie sehen können.